All Publications

Export 160 results:
Author Title Type [ Year(Asc)]
2010
The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M et al. J Viral Hepat, 2010 Aug, Volume 17, Issue 8, p.569-77, (2010)
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). Bansi L, Geretti A, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A et al. J Acquir Immune Defic Syndr, 2010 Apr, Volume 53, Issue 5, p.633-9, (2010)
Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Price H, Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D and Dunn D. Antivir Ther, 2010, Volume 15, Issue 2, p.203-11, (2010)
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Chilton D, Castro H, Lattimore S, Harrison L, Fearnhill E, Delpech V, Rice B, Pillay D and Dunn D. Antivir Ther, 2010, Volume 15, Issue 7, p.985-91, (2010)
2009
Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Murillo A, Mocroft A, Bonnet F, Clifford G, Touloumi G et al. AIDS, 2009 Sep 24, Volume 23, Issue 15, p.2029-37, (2009)
Virological response to initial antiretroviral regimens containing abacavir or tenofovir. Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J et al. J Infect Dis, 2009 Sep 01, Volume 200, Issue 5, p.710-4, (2009)
Clinical epidemiology of HIV-associated end-stage renal failure in the UK. Bansi L, Hughes A, Bhagani S, Mackie N, Leen C, Levy J, Edwards S, Connolly J, Holt S, Hendry B et al. AIDS, 2009 Nov 27, Volume 23, Issue 18, p.2517-21, (2009)
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? Grant A, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M et al. AIDS, 2009 Nov 27, Volume 23, Issue 18, p.2507-15, (2009)
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M et al. J Acquir Immune Defic Syndr, 2009 Nov 01, Volume 52, Issue 3, p.391-6, (2009)
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Geretti A, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D and Dunn D. Clin Infect Dis, 2009 May 01, Volume 48, Issue 9, p.1296-305, (2009)
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips A, Bansi L, Gilson R, Easterbrook P et al. Haematologica, 2009 Jun, Volume 94, Issue 6, p.875-80, (2009)
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. Sabin C, Smith C, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K et al. HIV Med, 2009 Jan, Volume 10, Issue 1, p.35-43, (2009)
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. Kesselring A, Wit F, Sabin C, Lundgren J, M Gill J, Gatell J, Rauch A, Montaner J, de Wolf F, Reiss P et al. AIDS, 2009 Aug 24, Volume 23, Issue 13, p.1689-99, (2009)
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo A, Mocroft A, Bonnet F, Clifford G, Karafoulidou A et al. Antivir Ther, 2009, Volume 14, Issue 8, p.1065-74, (2009)
2008
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. Lee K, Dunn D, Gilson R, Porter K, Bansi L, Hill T, Phillips A, Sabin C, Schwenk A, Leen C et al. AIDS, 2008 Oct 01, Volume 22, Issue 15, p.1943-50, (2008)
What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? Grover D, Copas A, Green H, Edwards S, Dunn D, Sabin C, Phillips A, Allen E and Pillay D. J Antimicrob Chemother, 2008 Mar, Volume 61, Issue 3, p.705-13, (2008)
Response to combination antiretroviral therapy: variation by age. Sabin C, Smith C, Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A et al. AIDS, 2008 Jul 31, Volume 22, Issue 12, p.1463-73, (2008)
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? Bansi L, Benzie A, Phillips A, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R et al. AIDS, 2008 Jan 30, Volume 22, Issue 3, p.349-56, (2008)
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. Easterbrook P, Phillips A, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn D et al. HIV Med, 2008 Jan, Volume 9, Issue 1, p.47-56, (2008)
Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3. Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J, Fisher M, Orkin C et al. J Acquir Immune Defic Syndr, 2008 Feb 01, Volume 47, Issue 2, p.202-5, (2008)
Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Dunn D, Geretti A, Green H, Fearnhill E, Pozniak A, Churchill D, Pillay D, Sabin C and Phillips A. Antivir Ther, 2008, Volume 13, Issue 6, p.771-7, (2008)
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A et al. Antivir Ther, 2008, Volume 13, Issue 5, p.675-85, (2008)